EMA receives Pfizer and BioNTech’s filing for conditional approval of COVID-19 vaccine in Europe
pharmafile | December 1, 2020 | News story | Manufacturing and Production, Sales and Marketing | BioNTech, COVID-19, EMA, Pfizer, Vaccine
Pfizer and BioNTech have officially submitted their application to secure conditional marketing authorisation to the European Medicines Agency (EMA) for its mRNA-based COVID-19 vaccine candidate BNT162b2, the agency has confirmed.
Hopes are high for Pfizer and BioNTech’s vaccine after it recently demonstrated 95% efficacy in global Phase 3 trials, with this efficacy maintained in at-risk groups such as over-65s. The developers said that, on successful approval, roll-out could commence before the end of the year.
The EMA will now review the application under an accelerated timeframe. The agency has been conducting a rolling review of all available data on the candidate since earlier in the year, enabling it to make an authorisation decision much faster than usual; it is expected that a final decision could be reached within weeks if the data supporting the application is strong enough.
Meanwhile, US rival Moderna, whose own mRNA vaccine showed final efficacy rates of 94.1%, announced its intentions to also file for approval in Europe this week.
Matt Fellows
Related Content
Gilead’s Veklury recommended by NICE for COVID-19 treatment
Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …
EC approves Pfizer’s Prevenar 20 to protect paediatric patients against pneumococcal disease
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Prevenar 20, …
EMA validates two applications for datopotamab deruxtecan for cancer treatments
AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications …